Covid 19 Research using Clinical Trials (Home Page)
Dabigatran etexilateWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
Correlated MeSH Terms (2)
Correlated HPO Terms (2)
|
Name (Synonyms) |
Correlation |
HP:0001635 | Congestive heart failure HPO | 0.38 |
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.21 |
There is one clinical trial.
Clinical Trials
The main objectives of this trial are to investigate the relative bioavailabilities of
rosuvastatin (Reference 1, Part 1) and dabigatran (Reference 2, Part 2) given alone and
together with BI 1323495 (Test 1, Test 2) following oral administration.
NCT04257032 Healthy Drug: Rosuvastatin Drug: Rosuvastatin + BI 1323495 Drug: Dabigatran etexilate Drug: Dabigatran etexilate + BI 1323495
Primary Outcomes
Measure: Area under the concentration-time curve of Rosuvastatin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) Time: up to 5 days
Measure: Maximum measured concentration of Rosuvastatin in plasma (Cmax) Time: up to 5 days
Measure: Area under the concentration-time curve of Dabigatran in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) Time: up to 4 days
Measure: Maximum measured concentration of Dabigatran in plasma (Cmax) Time: up to 4 days
Secondary Outcomes
Measure: Area under the concentration-time curve of Rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) Time: up to 5 days
Measure: Area under the concentration-time curve of Dabigatran in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) Time: up to 4 days
No related HPO nodes (Using clinical trials)